Corticosteroids
| Zeile 9: | Zeile 9: | ||
{{tp|p=32372026|t=ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis |pdf=|usr=}} | {{tp|p=32372026|t=ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis |pdf=|usr=}} | ||
{{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}} | {{tp|p=32341331|t=2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia |pdf=|usr=}} | ||
| + | {{tp|p=32133159|t=2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia |pdf=|usr=}} | ||
Version vom 18. Juni 2020, 12:56 Uhr
32149773 ä. Effectiveness of glucocorticoid therapy in patients with severe coronavirus disease 2019: protocol of a randomized controlled trial
32272008 2020. Early preemptive immunomodulators (corticosteroids) for severe pneumonia patients infected with SARS-CoV-2
32341100 2020. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective
32321620 ä. Corticosteroid use for 2019-nCoV infection: A double-edged sword
32283153 ä. Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-1
32122468 2020. On the use of corticosteroids for 2019-nCoV pneumonia
32043983 2020. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury
32372026 ä. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2, SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis
32341331 2020. A retrospective cohort study of methylprednisolone therapy in severe patients with COVID-19 pneumonia
32133159 2020. Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia
